Overview
TransMedics Q2 revenue grows 38% yr/yr, beating analyst expectations, per LSEG data
Net income for Q2 rises significantly, reflecting successful strategy execution
Company raises full-year 2025 revenue guidance, indicating confidence in growth
Outlook
TransMedics raises 2025 revenue guidance to $585 mln-$605 mln
Company targets 10,000 US NOP (National OCS Program) transplants by 2028
Result Drivers
OCS UTILIZATION - Revenue growth driven by increased utilization of Organ Care System, particularly in Liver and Heart through National OCS Program
AVIATION EXPANSION - Expansion and utilization of aviation fleet fueled NOP service revenue
R&D INVESTMENT - Increased operating expenses attributed to higher research and development investment
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Revenue | Beat | $157.40 mln | $147.90 mln (9 Analysts) |
Q2 Net Income | $34.90 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"
Wall Street's median 12-month price target for Transmedics Group Inc is $149.00, about 29.6% above its July 29 closing price of $104.83
The stock recently traded at 48 times the next 12-month earnings vs. a P/E of 41 three months ago
Press Release: ID:nPnXYVH1a
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.